We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

MINDRAY In-Vitro Diagnostics

As a global leader in in-vitro diagnostics, Mindray provides a wide range of efficient, reliable IVD solutions for la... read more Featured Products: More products

Download Mobile App





Mindray Presents Holistic IVD Solutions for Laboratories at Medlab Middle East 2023

By LabMedica International staff writers
Posted on 06 Feb 2023
Print article
Image: The latest innovations and solutions on display at Medlab Middle East 2023 (Photo courtesy of Mindray)
Image: The latest innovations and solutions on display at Medlab Middle East 2023 (Photo courtesy of Mindray)

Mindray (Shenzhen, China) is presenting the company’s holistic solutions in in-vitro diagnostics (IVD) at the 22nd edition of Medlab Middle East Congress taking place live, in-person from 6-9 February 2023.

At Medlab Middle East 2023, Mindray is showcasing its total IVD solutions and new technologies that cater to laboratories with all sample volumes, ranging from large-sized laboratories to mid-sized and small-sized ones. Mindray is also demonstrating how its M6000 Laboratory Automation System can empower ultra high volume laboratories with high processing speed, less hands-on time, great cost efficiency and standardized analytical quality. Mindray is also presenting its ALL IN ONE Hematology Solution that brings greater efficiency to hematology testing with simplified workflows and ease of operation. It enables end-to-end automation throughout the process, from tube sorting through to analysis of CBC, ESR, CRP, SAA, and HbA1c with a single EDTA tube, smear preparation, and slide reading. The solution is ideal for core or centralized laboratories with mid-to-high sample volumes and a high demand for turnaround times.

Also on display at the show is the CAL 8000 New Generation Cellular Analysis Line from Mindray that provides more power for large-scale laboratories in the hematology area. It has a higher throughput per square meter, upgraded labXpert Data Management Software, flexible layout design options, and other advanced functionalities. Combining Mindray's new MC-80 Digital Cell Morphology Analyzer, the CAL 8000 is taking hematology analysis automation to the next level. Mindray is also presenting its BC-700 revolutionary hematology analyzer series that incorporates both complete blood count (CBC) and erythrocyte sedimentation rate (ESR) tests, alongside the BS-600M chemistry analyzer that combines cutting-edge medical technology with advanced clinical applications and service processes for the screening and treatment for chronic diseases.

Related Links:
Mindray

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The study demonstrated that electric-field molecular fingerprinting can probe cancer (Photo courtesy of ACS Central Science, 2025, 10.1021/acscentsci.4c02164)

New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma

Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read more

Molecular Diagnostics

view channel
Image: The study validated the Lumipulse p-tau21 automated and scalable blood test system (Photo courtesy of Fujirebio)

Blood Test for Early Alzheimer's Detection Achieves Over 90% Accuracy

Alzheimer's disease (AD) is a debilitating condition and a leading cause of disability and death worldwide. The availability of reliable diagnostic tools is currently restricted, and diagnosis often relies... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.